PML-IV functions as a negative regulator of telomerase by interacting with TERT

Journal of Cell Science

Volumn 122, Issue 15, 2009, Pages 2613-2622

  Oh, Wonkyung ^a   Ghim, Jaewang ^a,b   Lee, Eun Woo ^a   Yang, Mi Ran ^a   Kim, Eui Tae ^a   Ahn, Jin Hyun ^a   Song, Jaewhan ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

PML; PML nuclear bodies; Telomerase; TERC; TERT

Indexed keywords

ALPHA INTERFERON; PROMYELOCYTIC LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN 4; SMALL INTERFERING RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION;

DOWN-REGULATION; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTERFERON-ALPHA; LIVER NEOPLASMS; LUNG NEOPLASMS; NUCLEAR PROTEINS; RNA, MESSENGER; TELOMERASE; TELOMERE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 69549138485     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.048066     Document Type: Article

References (54)

1. Artandi, S. E., Alson, S., Tietze, M. K., Sharpless, N. E., Ye, S., Greenberg, R. A., Castrillon, D. H., Horner, J. W., Weiler, S. R., Carrasco, R. D. et al. (2002). Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc. Natl. Acad. Sci. 99, 8191-8196.
2. Autexier, C. and Lue, N. F. (2006). The structure and function of telomerase reverse transcriptase. Annu. Rev. Biochem. 75, 493-517.
3. Beausejour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P. and Campisi, J. (2003). Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212-4222.
4. Bernardi, R. and Pandolfi, P. P. (2003). Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22, 9048-9057.
5. Bernardi, R. and Pandolfi, P. P. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8, 1006-1016.
6. Bischof, O., Kirsh, O., Pearson, M., Itahana, K., Pelicci, P. G. and Dejean, A. (2002). Deconstructing PML-induced premature senescence. EMBO J. 21, 3358-3369.
7. Blackburn, E. H. (2000). The end of the (DNA) line. Nat. Struct. Biol. 7, 847-850.
8. Blasco, M. A. (2003). Telomeres and cancer: a tale with many endings. Curr. Opin. Genet. Dev. 13, 70-76.
9. Blasco, M. A. (2005). Mice with bad ends: mouse models for the study of telomeres and telomerase in cancer and aging. EMBO J. 24, 1095-1103.
10. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S. and Wright, W. E. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352.
11. Bryan, T. M., Goodrich, K. J. and Cech, T. R. (2000). Telomerase RNA bound by protein motifs specific to telomerase reverse transcriptase. Mol. Cell 6, 493-499.
12. Chai, W., Ford, L. P., Lenertz, L., Wright, W. E. and Shay, J. W. (2002). Human Ku70/80 associates physically with telomerase through interaction with hTERT. J. Biol. Chem. 277, 47242-47247.
13. Cosme-Blanco, W., Shen, M. F., Lazar, A. J., Pathak, S., Lozano, G., Multani, A. S. and Chang, S. (2007). Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 8, 497-503.
14. Counter, C. M., Hahn, W. C., Wei, W., Caddle, S. D., Beijersbergen, R. L., Lansdorp, P. M., Sedivy, J. M. and Weinberg, R. A. (1998). Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. USA 95, 14723-14728.
15. Dalla Torre, C. A., Maciel, R. M., Pinheiro, N. A., Andrade, J. A., De Toledo, S. R., Villa, L. L. and Cerutti, J. M. (2002). TRAP-silver staining, a highly sensitive assay for measuring telomerase activity in tumor tissue and cell lines. Braz. J. Med. Biol. Res. 35, 65-68.
16. de Lange, T. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19, 2100-2110.
17. Dellaire, G. and Bazett-Jones, D. P. (2004). PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. BioEssays 26, 963-977.
18. Everett, R. D. and Chelbi-Alix, M. K. (2007). PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89, 819-830.
19. Feldser, D. M. and Greider, C. W. (2007). Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461-469.
20. Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K., Pandolfi, P. P., Will, H., Schneider, C. and Del Sal, G. (2000). Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19, 6185-6195.
21. Gao, C., Cheng, X., Lam, M., Liu, Y., Liu, Q., Chang, K. S. and Kao, H. Y. (2008). Signal-dependent regulation of transcription by histone deacetylase 7 (HDAC7) involves recruitment to PML nuclear bodies. Mol. Biol. Cell 19, 3020-3027.
22. Gonzalez-Suarez, E., Samper, E., Ramirez, A., Flores, J. M., Martin-Caballero, J., Jorcano, J. L. and Blasco, M. A. (2001). Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20, 2619-2630.
23. Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W. and Pandolfi, P. P. (2000). The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2, 730-736.
24. Harley, C. B. (2008). Telomerase and cancer therapeutics. Nat. Rev. Cancer 8, 167-179.
25. Ishov, A. M., Sotnikov, A. G., Negorev, D., Vladimirova, O. V., Neff, N., Kamitani, T., Yeh, E. T., Strauss, J. F., 3rd and Maul, G. G. (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147, 221-234.
26. Jensen, K., Shiels, C. and Freemont, P. S. (2001). PML protein isoforms and the RBCC/TRIM motif. Oncogene 20, 7223-7233.
27. Kang, H., Kim, E. T., Lee, H. R., Park, J. J., Go, Y. Y., Choi, C. Y. and Ahn, J. H. (2006). Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J. Gen. Virol. 87, 2181-2190.
28. Kang, S. S., Kwon, T., Kwon, D. Y. and Do, S. I. (1999). Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274, 13085-13090.
29. Kharbanda, S., Kumar, V., Dhar, S., Pandey, P., Chen, C., Majumder, P., Yuan, Z. M., Whang, Y., Strauss, W., Pandita, T. K. et al. (2000). Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr. Biol. 10, 568-575.
30. Kim, J. H., Park, S. M., Kang, M. R., Oh, S. Y., Lee, T. H., Muller, M. T. and Chung, I. K. (2005). Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev. 19, 776-781.
31. Kim, N. W. and Wu, F. (1997). Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 25, 2595-2597.
32. Lallemand-Breitenbach, V., Zhu, J., Puvion, F., Koken, M., Honore, N., Doubeikovsky, A., Duprez, E., Pandolfi, P. P., Puvion, E., Freemont, P. et al. (2001). Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193, 1361-1371.
33. Lee, J., Sung, Y. H., Cheong, C., Choi, Y. S., Jeon, H. K., Sun, W., Hahn, W. C., Ishikawa, F. and Lee, H. W. (2008). TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 27, 3754-3760.
34. Liu, J. P. (1999). Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 13, 2091-2104.
35. Massard, C., Zermati, Y., Pauleau, A. L., Larochette, N., Metivier, D., Sabatier, L., Kroemer, G. and Soria, J. C. (2006). hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 25, 4505-4514.
36. Masutomi, K., Yu, E. Y., Khurts, S., Ben-Porath, I., Currier, J. L., Metz, G. B., Brooks, M. W., Kaneko, S., Murakami, S., DeCaprio, J. A. et al. (2003). Telomerase maintains telomere structure in normal human cells. Cell 114, 241-253.
37. McEachern, M. J., Krauskopf, A. and Blackburn, E. H. (2000). Telomeres and their control. Annu. Rev. Genet. 34, 331-358.
38. Melnick, A. and Licht, J. D. (1999). Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167-3215.
39. Nisole, S., Stoye, J. P. and Saib, A. (2005). TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev. Microbiol. 3, 799-808.
40. Oh, W., Lee, E. W., Sung, Y. H., Yang, M. R., Ghim, J., Lee, H. W. and Song, J. (2006). Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J. Biol. Chem. 281, 17457-17465.
41. Pearson, M. and Pelicci, P. G. (2001). PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20, 7250-7256.
42. Reineke, E. L., Lam, M., Liu, Q., Liu, Y., Stanya, K. J., Chang, K. S., Means, A. R. and Kao, H. Y. (2008). Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol. Cell. Biol. 28, 997-1006.
43. Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., Riganelli, D., Zanaria, E., Messali, S., Cainarca, S. et al. (2001). The tripartite motif family identifies cell compartments. EMBO J. 20, 2140-2151.
44. Seimiya, H., Tanji, M., Oh-hara, T., Tomida, A., Naasani, I. and Tsuruo, T. (1999). Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochem. Biophys. Res. Commun. 260, 365-370.
45. Sharpless, N. E. and DePinho, R. A. (2004). Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 113, 160-168.
46. Stampfer, M. R., Garbe, J., Levine, G., Lichtsteiner, S., Vasserot, A. P. and Yaswen, P. (2001). Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc. Natl. Acad. Sci. USA 98, 4498-4503.
47. Takahashi, Y., Lallemand-Breitenbach, V., Zhu, J. and de The, H. (2004). PML nuclear bodies and apoptosis. Oncogene 23, 2819-2824.
48. Wei, X., Yu, Z. K., Ramalingam, A., Grossman, S. R., Yu, J. H., Bloch, D. B. and Maki, C. G. (2003). Physical and functional interactions between PML and MDM2. J. Biol. Chem. 278, 29288-29297.
49. Wu, Y. L., Dudognon, C., Nguyen, E., Hillion, J., Pendino, F., Tarkanyi, I., Aradi, J., Lanotte, M., Tong, J. H., Chen, G. Q. et al. (2006). Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J. Cell Sci. 119, 2797-2806.
50. Xia, J., Peng, Y., Mian, I. S. and Lue, N. F. (2000). Identification of functionally important domains in the N-terminal region of telomerase reverse transcriptase. Mol. Cell. Biol. 20, 5196-5207.
51. Xu, D., Wang, Q., Gruber, A., Bjorkholm, M., Chen, Z., Zaid, A., Selivanova, G., Peterson, C., Wiman, K. G. and Pisa, P. (2000). Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19, 5123-5133.
52. Zhang, X., Mar, V., Zhou, W., Harrington, L. and Robinson, M. O. (1999). Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13, 2388-2399.
53. Zheng, P., Guo, Y., Niu, Q., Levy, D. E., Dyck, J. A., Lu, S., Sheiman, L. A. and Liu, Y. (1998). Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 396, 373-376.
54. Zhong, S., Muller, S., Ronchetti, S., Freemont, P. S., Dejean, A. and Pandolfi, P. P. (2000). Role of SUMO-1-modified PML in nuclear body formation. Blood 95, 2748-2752.